Get started
Author

O. Tomé

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
2014 · G. von Minckwitz, S. Loibl, et al. · Annals of Oncology · 138
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group
2005 · F. Hilpert, A. Stähle, et al. · Supportive Care in Cancer · 71
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial
2010 · M. Kaufmann, N. Maass, et al. · European Journal of Cancer · 39
Breast Cancer Treatment with Everolimus and Exemestane for Er+ Women - Results of the 2Nd Interim Analysis of the Non-Interventional Trial Brawo
2014 · P.A. Fasching, T. Decker, et al. · Annals of Oncology · 16
815MO The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
2020 · B. You, L. Van Wagensveld, et al. · Annals of Oncology · 8
PDF
Abstract P6-09-10: Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
2017 · R Wuerstlein, O Gluz, et al. · Cancer Research · 7
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study
2025 · Thorsten Kühn, Maggie Banys-Paluchowski, et al. · British journal of surgery · 6
Erhöhtes Risiko von Spätfolgen bei zu kurzem Intervall zwischen intraoperativem Tumorbettboost und Mammahomogenbestrahlung
2008 · E. Blank, G. Welzel, et al. · Geburtshilfe und Frauenheilkunde · 5
Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC)
2017 · H. Woopen, P. Wimberger, et al. · Annals of Oncology · 3
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A planed 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR).
2010 · W. Meier, W. Lichtenegger, et al. · Journal of Clinical Oncology · 3
Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study
2018 · V Möbus, R Mahlberg, et al. · Cancer Research · 2
Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC) (on behalf of the North-Eastern German Society of Gynaecological Oncology, NOGGO)
2017 · J. Sehouli, A. Mustea, et al. · Annals of Oncology · 2
PDF
The influence of the interval between IORT during breast-conserving surgery and external beam radiotherapy (EBRT) on late toxicity
2008 · G. Welzel, E. Blank, et al. · Journal of Clinical Oncology · 2
38 Influence of amifostine on neuroprotection in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group
2003 · P. Wimberger, R. Kimmig, et al. · European Journal of Cancer Supplements · 2
74MO Prognostic value of PDL1 expression and correlation with HRD status in high-grade serous ovarian cancer: An ancillary analysis of the PAOLA-1/ENGOT-ov25 trial, a GINECO study
2025 · I. Treilleux, S. Cyrille, et al. · ESMO Open · 1
PDF
1573P Developing a patient-related predictive model for the occurrence of CINV (NOGGO-EMRISK trial): Prospective, multicentre study in Germany
2022 · J. Sehouli, G. Oskay-Öczelik, et al. · Annals of Oncology
PDF
98P Final results from AVANTI, a multicentre German observational study of first-line bevacizumab (BEV) + chemotherapy (CT) in >2000 patients (pts) with advanced breast cancer (aBC)
2021 · V. Mueller, M. Ruhnke, et al. · Annals of Oncology
PDF
Intraoperativen Boost-Bestrahlung des Mammakarzinoms
2008 · OM Tomé, K Grosse, et al. · Geburtshilfe und Frauenheilkunde
Erhöhtes Risiko von Spätfolgen bei zu kurzem Intervall zwischen intraoperativem Tumorbettboost und Mammahomogenbestrahlung
2008 · E Blank, G Welzel, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Didaktische Optimierung des Praktikums in Gynäkologie und Geburtshilfe nach der neuen ärztlichen Approbationsordnung: Konzept und Resultate
2008 · K Grosse, C Kaden, et al. · Geburtshilfe und Frauenheilkunde
Operative Aspekte der intraoperativen Bestrahlung im Rahmen der Brust erhaltenden Therapie des Mammakarzinoms
2008 · O Tomé, U Kraus-Tiefenbacher, et al. · Geburtshilfe und Frauenheilkunde
359 Neuroprotection With Amifostine in The 1St-Line Treatment of Advanced Ovarian Cancer With Carboplatin/Taxane-Based Chemotherapy – A Double-Blind, Placebo-Controlled, Randomized Phase Ii-Study From The Ago Ovarian Cancer Study Group
2004 · A.K. Belau, F. Hilpert, et al. · International Journal of Gynecological Cancer
Evaluation of the new polyclonal rabbit anti-human HER2/neu antibody — Overexpression of HER2/neu in ovarian cancer is associated with shortened overall survival
1999 · R. Emig, C. Zeeb, et al. · European Journal of Cancer
Works count: 23
Citation count: 305
H-index: 6
I10-index: 4
Year
Topic
Type